Papers by Maria Vittoria Cossu
Antiviral Therapy, 2016
Background Dolutegravir plus darunavir provide a high genetic barrier to HIV-1 resistance and are... more Background Dolutegravir plus darunavir provide a high genetic barrier to HIV-1 resistance and are suitable for simple salvage regimens. Methods All HIV-1-infected subjects treated with dolutegravir plus boosted darunavir dual therapy between March 2011 and September 2015 were included in an observational cohort. Data were collected at baseline and at weeks 4, 12, 24 and 48. Results We enrolled 113 subjects. After week 24, one was lost at follow-up, one dropped out for grade 2 elevation of liver enzymes, one died from illicit drug abuse and one from cancer-related sepsis. The mean age was 51, 26.5% were female and 9.7% were non-Caucasian. Twenty had never experienced failure. A total of 99 had reverse-transcriptase (RT) mutations, 87 had protease inhibitor mutations and 12 had integrase strand transfer inhibitor (INSTI) mutations. Viraemic patients declined from baseline to week 24 from 43.4% to 6.2%, the remainder being due to high baseline viraemia or adherence issues. The proporti...
O_01 A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined ... more O_01 A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Positive, Antiretroviral-experienced Patients with Stable Viral Suppression Alberto Borghetti1, Gianmaria Baldin1, Amedeo Capetti2, Gaetana Sterrantino3, Stefano Rusconi4, Alessandra Latini5, Andrea Giacometti6, Giordano Madeddu7, Chiara Picarelli1, Ramona De Marco1, Maria Vittoria Cossu2, Filippo Lagi3, Letizia Oreni4, Roberto Cauda1, Andrea De Luca8, Simona Di Giambenedetto1 and the ODOACRE Study Group 1. Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome.; 2. Division of Infectious Diseases, Department of Infectious Diseases , Luigi Sacco University Hospital, Milan, Italy; 3. Division of Tropical and Infectious Diseases, "Careggi" Hospital, Florence, Italy ;4. Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy; ...
Drug design, development and therapy, 2014
We designed two Phase I studies that assessed healthy volunteers in order to evaluate the safety ... more We designed two Phase I studies that assessed healthy volunteers in order to evaluate the safety and to optimize the dosing of the combination of the drugs isosorbide dinitrate, a nitric oxide donor, and ibuprofen, a nonsteroidal antiinflammatory drug. We designed these studies with the aim of designing a Phase II trial to evaluate the drugs' efficacy in patients affected by Duchenne muscular dystrophy. For the first trial, ISOFEN1, a single-dose, randomized-sequence, open-label, active control, three-treatment cross-over study, was aimed at comparing the pharmacokinetics of ibuprofen 200 mg and isosorbide dinitrate 20 mg when given alone and concomitantly. The pharmacokinetics of ibuprofen given alone versus ibuprofen given concomitantly with isosorbide dinitrate were similar, as documented by the lack of statistically significant differences in the main drug's pharmacokinetic parameters (time to maximal concentration [Tmax], maximal concentration [Cmax], area under the cur...
Uploads
Papers by Maria Vittoria Cossu